写真:辻 大樹

辻 大樹(TSUJI Daiki)
薬学部薬学科(臨床薬効解析学分野) 講師
薬学研究院(臨床薬効解析学教室) 講師(兼務)


1998年3月 明治薬科大学薬学部衛生薬学科卒業
2000年3月 明治薬科大学大学院薬学研究科臨床薬学専攻修士課程修了








  • がん化学療法における薬物有害反応に関する研究
  • 遺伝子情報に基づくがん化学療法の薬物応答性に関する研究
  • 抗がん薬の薬物間相互作用に関する研究




2000年4月~2005年3月 聖隷浜松病院薬剤部
2005年4月~2006年3月 聖隷淡路病院
2006年4月~2009年7月 聖隷浜松病院薬剤部
2009年8月~2017年3月 静岡県立大学薬学部助教
2017年4月 静岡県立大学薬学部講師


2013年 第1回 江口記念がん優秀論文賞


静岡県病院薬剤師会 がん治療を考える薬剤師の会 幹事
静岡県病院薬剤師会 学術部 がん専門薬剤師部門特別委員


  1. A Retrospective Analysis of the Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy. Ann Pharmacother., in press 2019
  2. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer, 27, 1139-1147. 2019
  3. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). J Pharm Health Care Sci., 4, 31. 2018
  4. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy. Support Care Cancer, 26, 1505-1513. 2018
  5. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study. Pharmacogenomics J., 17, 435-440. 2017
  6. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. Eur. J. Clin. Pharmacol., 73, 1033–1039. 2017
  7. A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype. Clin. Exp. Allergy, 47, 1374-1382. 2017
  8. ドキソルビシン/シクロホスファミド併用療法施行乳がん患者における化学療法誘発性悪心・嘔吐に対するアプレピタントの効果の検討、医療薬学、Vol.43、No.1、pp1-8、2017
  9. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients: A hospital-based observational study. Medicine (Baltimore), 95, e5151. 2016
  10. Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment. Eur J Clin Pharmacol., 72, 1177-1183. 2016 
  11. Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression. Biol Pharm Bull., 39, 1508-1513. 2016
  12. Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification. Anal Chim Acta., 916, 112-119. 2016
  13. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy. Seizure, 33, 76-80. 2015
  14. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther. Drug Monit., 38, 706-710. 2016
  15. Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. Eur. J. Clin. Pharmacol., 72, 555-562. 2016
  16. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug Metab. Pharmacokinet., Drug Metab. Pharmacokinrt., 30, 149–153. 2015
  17. Plasma vitamin K concentrations depend on CYP4F2 polymorphism and influence on anticoagulation in Japanese patients with warfarin therapy. Thromb. Res., 135, 861-866. 2015
  18. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metabolism and Pharmacokinetics., Drug Metab. Pharmacokinrt., 30, 227–230. 2015
  19. Identification of anti-CD98 antibody mimotopes for inducing antibodies with antitumor activity by mimotope immunization. Cancer Sci. Cancer Sci., 105, 396-401. 2014
  20. Influence of uridine diphosphate glucuronosyltransferase (UGT) 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients. Ther Drug Monit., 36, 406-409. 2014
  21. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy. Epilepsy Res., 108, 1046-1051. 2014
  22. ゲムシタビン施行切除不能膵癌患者に於ける予後因子の検討、医療薬学、Vol.40、No.12、pp734-741、2014
  23. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin. Chemotherapy., 59, 407-413. 2013
  24. Association of ABCB1 polymorphisms with the antiemetic efficacy of granisetron plus dexamethasone in breast cancer patients. Drug Metab. Pharmacokinet.,28, 299-304. 2013
  25. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinrt.,28, 164-168. 2013.
  26. Polymorphisms of the UDP-Glucuronosyl Transferase 1A Genes Are Associated with Adverse Events in Cancer Patients Receiving Irinotecan-Based Chemotherapy.Tohoku J. Exp. Med., 229, 107-114. 2013
  27. Analysis of risk factors of drug-induced lung injury in patients receiving gemcitabine treatment. Gan To Kagaku Ryoho., 39, 787-792. 2012
  28. Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial. Support Care Cancer., 20, 1057-1064. 2012
  29. An artifact derived from pseudogene led to the discovery of micro RNA binding site polymorphism in 3′-untranslated region of human dihydrofolate reductase gene. Drug Metab. Pharmacokinet., 27, 263-267. 2012
  30. Genotype distributions and allele frequencies of possible major depressive disorder-associated single nucleotide polymorphisms, cyclic adenosine monophosphate response element binding protein 1 rs4675690 and Piccolo rs2522833, in a Japanese population. Biol. Pharm. Bull., 35, 265-268. 2012
  31. Dihydrofolate reductase gene intronic 19-bp deletion polymorphisms in a Japanese population. Drug Metab. Pharmacokinet., 25, 516-518. 2010
  32. Generation of AcGFP-labeled single-chain Fv against 5-methyl 2′-deoxycytidine from a hyperimmunized mouse using phage display technology. Protein Eng. Des. Sel., 23, 881-888. 2010
  33. ワルファリン服用患者における出血リスクに対するプロトンポンプ阻害薬併用の影響. 日本病院薬剤師会雑誌, 46, 535-538. 2010
  34. ドセタキセルとワルファリンの薬物相互作用によるプロトロンビン時間の変動に関する検討. 医療薬学, 36, 802-806. 2010
  35. 当院におけるベバシズマブ(アバスチン®)分注液の懸濁浮遊物について、あたらしい眼、Vol.26、No.4、pp573-575、2009
  36. CYP2C19遺伝子多型に基づくHelicobactor pylori二次除菌療法の検討、医療薬学、Vol.33、No.3、pp254-259、2007
  37. 抗悪性腫瘍剤の規格適正化への取り組みが薬剤費に及ぼす影響Vol.43、No12、pp1697-1699
  38. 高脂血症患者における服薬コンプライアンスの検討:パーソナルコンピュータを利用した服薬コンプライアンス測定器の使用、医療薬学、Vol.31、No.7、pp527-532
  39. Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy, Nippon Rinsho. 63 Suppl 12:450-3.( 2005).

  1. 辻 大樹:薬物療法問題集 コモンな50疾患・150題で実力がつく! 肺がん. 月刊薬事, 60, 228-232 (2018)
  2. 山本圭祐、辻 大樹:薬物療法問題集 コモンな50疾患・150題で実力がつく! 前立腺がん. 月刊薬事, 60, 266-270 (2018)
  3. 辻 大樹:目から鱗のがん薬物療法 ─薬学的視点からみたケーススタディ─ 一歩進んだ薬剤師によるがん化学療法による悪心・嘔吐の臨床研究. Cancer Board Square, 3, 124–128 (2017)
  4. 辻 大樹:がん領域の医薬品情報:ゲムシタビン. The Journal of Oncology Pharmacy, 5, 3-6 (2013)
  5. 辻 大樹、伊藤邦彦:薬剤師主導臨床試験の立案. 薬局, 63, 144-151 (2012)
  6. 辻 大樹、伊藤邦彦:薬効モニタリングの実践-9 胃・十二指腸潰瘍. 薬局, 62, 85-89 (2011)
  7. 辻 大樹、伊藤邦彦:適切な支持療法薬の選択により患者のQOLを高める. 薬局, 61, 57-66 (2010)
  8. さあ、はじめよう!NST事例で分かる栄養療法の進め方、株式会社中山書店、東京、第2部 pp-80-241、2007
  9. アプライドセラピューティクス―症例解析にもとづく薬物治療 (5)、じほう、97. pp30-45、2002